ACROBiosystems Expands Its Presence in France with The HIVE Innovation Center

ACROBiosystems Strengthens Its French Presence

In an exciting development for the biotechnology sector, ACROBiosystems has inaugurated a dedicated office within The HIVE Innovation Center, located in the vibrant Campus Grand Parc of Villejuif, France. This strategic move underscores the company's commitment to deepening its foothold in the French market and enhancing collaboration within the thriving local ecosystem.

Founded in 2010, ACROBiosystems has rapidly emerged as a key player in the global biopharmaceutical and healthcare industries. With a workforce nearing 1,000 employees dispersed across various global offices and R&D centers, the company is known for its comprehensive portfolio that spans the entire drug development cycle. This encompasses everything from recombinant proteins and antibodies to GMP-certified scientific services tailored to clients' specific needs.

The HIVE Innovation Center serves as a platform for ACROBiosystems to foster essential collaborations with other biotech companies, hospitals, and clinical research organizations located within the Campus Grand Parc. This integrated environment is designed to facilitate interaction and synergy, propelling the development of innovative cancer therapies and other cutting-edge medical solutions.

A Hub for Collaboration

The HIVE Innovation Center is more than just a physical space for ACROBiosystems; it represents a strategic hub for ongoing research and collaboration. This space has been specifically created to enhance day-to-day interactions among various life sciences stakeholders, an element that traditional office settings may lack.

Mike Chen, the President and CEO of ACROBiosystems, emphasized the significance of their new location: “Establishing our presence at The HIVE places us right in the heart of where our partners innovate. Our role extends beyond that of a conventional corporate office; we are here to engage deeply with the local community, collaborated with scientists who are shaping the future of therapies in areas like oncology and immuno-oncology.”

Furthermore, since becoming a member of the Paris-Saclay Cancer Cluster in 2025, ACROBiosystems is actively participating in the local bio-community, building networks that are crucial for the advancement of life sciences. This alignment not only reinforces the company's operational strategy but also positions it ideally to support the research efforts necessary for developing the next generation of medical treatments.

Global Reach with Local Roots

In establishing its facility within The HIVE, ACROBiosystems is showcasing its commitment to both global and local objectives. The company aims to seamlessly integrate its international processes with the localized expertise found within the Campus Grand Parc’s dynamic bioscience ecosystem. This balancing act is crucial, as it allows ACROBiosystems to leverage its global resources while cultivating meaningful relationships within the French health innovation community.

With this new office, ACROBiosystems reinforces its status as a trusted partner in the biopharmaceutical landscape, contributing not just products but valuable insights and support throughout the clinical development stages. The implications of this strategic move are vast, promising enhanced interactions that will accelerate the pace of innovation within the industry.

Founded with a vision to create tangible value in the biopharmaceutical field, ACROBiosystems is committed to driving advancements in targeted therapies, immunotherapeutics, and more. The company’s trajectory is set to continue its upward momentum, thanks to its strategic initiatives and dedication to fostering partnerships that align with its mission.

ACROBiosystems’ presence in The HIVE is a promising sign for the future of the biotech industry in France and reflects a broader trend of strengthening local competencies to address global health challenges. As the company drives forward, it aims to nurture a collaborative environment that is exciting not just for its operations but also for the entire French biotechnology ecosystem.